Lithium Effect on Thyroid
All patients receiving lithium therapy require periodic thyroid evaluation because lithium may induce goiter and hypothyroidism 1. Lithium accumulates in the thyroid gland at concentrations 3-4 times higher than plasma levels and disrupts multiple aspects of thyroid hormone synthesis, release, and peripheral metabolism 2.
Mechanism of Thyroid Dysfunction
Lithium interferes with thyroid function through several pathways:
- Inhibits thyroid hormone synthesis and release from follicular cells
- Blocks iodination of tyrosines and disrupts their coupling in thyroglobulin
- Reduces peripheral deiodination of T4 to T3 by decreasing type 1 and 2 deiodinase activity
- Enhances thyroid autoimmunity by augmenting B lymphocyte activity and altering T cell ratios 2, 3
The FDA label explicitly states that pre-existing thyroid disorders do not necessarily contraindicate lithium, but careful monitoring during stabilization and maintenance is essential 4.
Clinical Manifestations
Hypothyroidism and goiter are the most common thyroid abnormalities in patients on long-term lithium therapy 3. Recent data from a large Asian cohort showed lithium increased hypothyroidism risk 2-fold (aHR 2.00,95% CI 1.72-2.33) compared to other mood stabilizers 5. Hyperthyroidism occurs rarely but is documented 3, 5.
The risk is dose-dependent: patients with lithium levels <0.5 mEq/L had mean TSH increases of 0.52 mIU/L, while those with levels >0.8 mEq/L had increases of 2.16 mIU/L 6. Lithium levels above 0.50 mEq/L represent the threshold associated with hypothyroidism risk 5.
Monitoring Protocol
Before initiating lithium:
- Measure TSH, free T4, free T3
- Check anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies
- Perform thyroid ultrasound 2
During lithium therapy:
- Monitor TSH every 6 months if thyroid function is normal 1, 7
- More frequent monitoring (every 3-6 months) is warranted for:
The evidence shows that 6-monthly testing is appropriate, as most thyroid dysfunction manifests within 3 years of starting lithium (91.4% of cases) 7. Testing more frequently than every 6 months represents poor adherence to guidelines and is unnecessary 7.
Management of Lithium-Induced Hypothyroidism
When subclinical hypothyroidism develops (elevated TSH, normal free T4):
- Do not immediately discontinue lithium if it is providing psychiatric benefit
- Initiate levothyroxine supplementation while continuing lithium 4
- The FDA label explicitly states: "Where hypothyroidism occurs during lithium stabilization and maintenance, supplemental thyroid treatment may be used" 4
Important caveat: In the first 3 months after starting lithium, subclinical hypothyroidism may spontaneously normalize without intervention in approximately 50% of cases 7. Consider observation with repeat testing before initiating thyroid replacement in this early period, unless TSH is markedly elevated (>10 mIU/L) or symptoms are present.
For overt hypothyroidism (elevated TSH, low free T4):
- Start levothyroxine replacement immediately
- Continue lithium if psychiatrically indicated
- Monitor TSH every 6-8 weeks until stable, then every 6 months
Risk-Benefit Considerations
While lithium carries thyroid risks, the alternative mood stabilizers (valproate, olanzapine, quetiapine, risperidone) showed reduced likelihood of thyroid dysfunction compared to lithium 5. However, lithium remains the gold standard for bipolar disorder prophylaxis and suicide risk reduction. The thyroid complications are manageable with monitoring and levothyroxine supplementation, making them acceptable risks given lithium's psychiatric benefits.
The risk of advanced kidney disease (CKD stage 4+) was not significantly different between lithium and other mood stabilizers 5, though mild CKD (stage 3) risk was modestly elevated (aHR 1.35).
Key Clinical Pitfalls
- Do not rely solely on clinical symptoms to detect thyroid dysfunction—many patients remain asymptomatic until TSH is significantly elevated
- Do not stop lithium abruptly when hypothyroidism develops—this increases risk of psychiatric relapse; add thyroid replacement instead
- Do not assume normal baseline thyroid function eliminates risk—lithium can induce de novo thyroid dysfunction even in previously healthy glands
- Do not test TSH more frequently than every 6 months in stable patients—this represents unnecessary healthcare utilization 7